Chewy Goes Public; ArQule study on cancer

<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The stock market entered the session of Friday morning under pressure as investors sought once again to evaluate economic data in light of their willingness to see the Federal Reserve reduce interest rates to make monetary policy more accommodative.Finance markets have indicated a likely decline in about 40 points for the previous month. Dow Jones Industrial Average (DJINDICES: ^ DJI). Similarly, S & amp; P 500 (SNPINDEX: ^ GSPC) was about to lose about 9 points depending on the activity of the futures markets, and the Nasdaq Composite (NASDAQINDEX: ^ IXIC) "data-reactid =" 11 "> The stock market entered the Friday morning session under pressure, as investors again sought to evaluate economic data in light of their desire to see the Federal Reserve reduce rates more monetary markets, the futures markets have indicated a likely decrease of about 40 points Dow Jones Industrial Average (DJINDICES: ^ DJI). Similarly, S & P 500 (SNPINDEX: ^ GSPC) was about to lose about 9 points depending on the activity of the futures markets, and the Nasdaq Composite (NASDAQINDEX: ^ IXIC) indicates a drop of about 65 points.

<p class = "web-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Despite the downward movement of equity futures There was a lot of enthusiasm to start the day on Wall Street. Soft (NYSE: CHWY) hopes to continue the series of successful initial public offerings among promising innovative companies. At the same time, ArQule (NASDAQ: ARQL) A promising news in the fight against cancer has been announced. The first results of a study, which prompt many of them to look for the future success of the biopharmaceutical company. "data-reactid =" 12 "> Despite the decline in equity futures, Wall has sparked a lot of enthusiasm Street to start the day. Specialist in pet products Soft (NYSE: CHWY) hopes to continue the series of successful initial public offerings among promising innovative companies. At the same time, ArQule (NASDAQ: ARQL) announced promising news in the fight against cancer, with the first results of studies that encourage many of them to look for the future success of the biopharmaceutical company.

Barking a business

Chewy's shares were expected to be open for trading for the first time today as its shares are listed on the New York Stock Exchange. The company specializing in pet products has set the price of its initial public offering at $ 22 per share, which is higher than the maximum of the last expected range, from $ 19 to $ 21 per share.

More

Source of the image: Chewy.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Chewy aroused a lot of interest investors because of rising demand for pet-related products. Consumers love their pets and are willing to spend money on them. Chewy has managed to satisfy the demand with high-end products that resonate well for pet lovers. This is not surprising given that the majority shareholder of the company is the private operator PetSmart. "Data-reactid =" 27 "> Chewy has attracted a lot of interest from investors due to rising demand for pet products Chewy has been able to meet demand with high-end products that resonate This is no wonder, since the majority shareholder of the company is PetSmart, the private pet retail operator.

Some critics have noted that Chewy's business model was alarmingly similar to the unfortunate Pets.com, which survives 20 years later and is one of the most recognizable symbols of the Internet stock bubble at the end of the year. 1990s and early 2000s. The fact that Chewy's still does not make a profit feeds this narrative.

However, consumer behavior has changed dramatically over these two decades. The boom in e-commerce has made pet owners not only receptive, but they have insisted that pet products be delivered directly to their homes, and even if the lure of the Visit a brick and mortar place that hosts their pets has not gone. completely, Chewy offers the valuable service of bringing sometimes bulky items directly to homes. While the pet retailer is preparing to raise more than $ 1 billion during its IPO, pet owners can expect to see a lot more from the company at the same time. 'to come up.

ArQule is making progress

At the same time, ArQule shares climbed 47% in pre-market trading, as investors reacted favorably to publication of study data by biopharmacy. Clinical proof of concept data from the ArQule Phase 1 study of the ARQ 531 treatment candidate in patients with recurrent / refractory hematologic malignancies have shown promising results.

The ARQ 531 demonstrated substantial antitumor activity in the study, with four out of six patients with chronic lymphocytic leukemia having partial responses to treatment. In addition, the study revealed a partial response in his first patient suffering from Richter's Disease Transformation. ArQule also includes cohorts of patients with small lymphocytic leukemia, Waldenström's macroglobulinemia and other non-Hodgkin's B-cell lymphoma.

The story continues